COVID-19 adverse outcome pathway (WP4891)

Homo sapiens

Authors

Penny Nymark , Friederike Ehrhart , Egon Willighagen , Chris Evelo , and Eric Weitz

Activity

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

• Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor (2022).
• Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients (2022).
• AMP5A modulates Toll-like receptors 7 and 8 single-stranded RNA immune responses in PMA-differentiated THP-1 and PBMC (2022).
• Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies (2022).
• Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework (2021).
• Exploring the pharmacological mechanism of Duhuo Jisheng Decoction in treating intervertebral disc degeneration based on network pharmacology (2023).
• Identification of the Genetic Influence of SARS-CoV-2 Infections on IgA Nephropathy Based on Bioinformatics Method (2023).
• Identification of host genomic biomarkers from multiple transcriptomics datasets for diagnosis and therapies of SARS-CoV-2 infections (2023).
• Single-cell ‘omic profiles of human aortic endothelial cells in vitro and human atherosclerotic lesions ex vivo reveal heterogeneity of endothelial subtype and response to activating perturbations (2024).
• Statistical and network analyses reveal mechanisms for the enhancement of macrophage immunity by manganese in Mycobacterium tuberculosis infection (2024).
• The differential expression of adipose tissue genes in short, medium and long-term periods after bariatric surgery (2024).
• Repurposing Astragalus Polysaccharide PG2 for Inhibiting ACE2 and SARS-CoV-2 Spike Syncytial Formation and Anti-Inflammatory Effects (2023).

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Adverse Outcome Pathways COVID-19

Annotations

Disease Ontology

viral infectious disease COVID-19 pulmonary fibrosis severe acute respiratory syndrome

Pathway Ontology

respiratory system disease pathway signaling pathway

References

1. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. Circ Res. 2000 Sep 1;87(5):E1-9. PubMed Europe PMC Scholia
2. Nano-risk Science: application of toxicogenomics in an adverse outcome pathway framework for risk assessment of multi-walled carbon nanotubes. Labib S, Williams A, Yauk CL, Nikota JK, Wallin H, Vogel U, et al. Part Fibre Toxicol. 2016 Mar 15;13:15. PubMed Europe PMC Scholia
3. A Data Fusion Pipeline for Generating and Enriching Adverse Outcome Pathway Descriptions. Nymark P, Rieswijk L, Ehrhart F, Jeliazkova N, Tsiliki G, Sarimveis H, et al. Toxicol Sci. 2018 Mar 1;162(1):264–75. PubMed Europe PMC Scholia